Supplementary Data from Preclinical Activity of the DLL3-Targeted T-cell Engager MK-6070 in Neuroendocrine Prostate Cancer

Supplementary Figure 1 data shows MK-6070 mediated T cell cytotoxicity in vitro. Supplementary Figure 2 measures T cell activation after MK-6070. Supplementary Figure 3 shows anti-tumor activity of MK-6070 in prostate cancer xenograft models. Supplementary Figure 4 characterizes the WCM PDX model after MK-6070. Supplementary Figure 5 evaluates response to MK-6070 in DLL3 heterogeneous models.